3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to
the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in
older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this
population will also be studied. These results will be used to design larger studies of
MSDC-0160 in persons with mild Alzheimer's disease.